The combined treatment with novel platinum(II) complex and anti-MUC1 increases apoptotic response in MDA-MB-231 breast cancer cells

详细信息    查看全文

• 作者：Agnieszka Gornowicz ; Anna Bielawska…
• 关键词：Anti ; MUC1 ; Anticancer drugs ; Platinum complexes ; Targeted therapy ; Apoptotic markers
• 刊名：Molecular and Cellular Biochemistry
• 出版年：2015
• 出版时间：October 2015
• 年：2015
• 卷：408
• 期：1-2
• 页码：103-113
• 全文大小：4,406 KB
• 参考文献：1.Zhou Y, Rajabi H, Kufe D (2011) Mucin 1 C-terminal subunit oncoprotein is a target for small-molecule inhibitors. Mol Pharmacol 79:886-93. doi:10.-124/?mol.-10.-70797 PubMed Central CrossRef PubMed
  2.Constantinou PE, Danysh BP, Dharmaraj N, Carson DD (2011) Transmembrane mucins as novel therapeutic targets. Expert Rev Endocrinol Metab 6:835-48. doi:10.-586/?eem.-1.-0 PubMed Central CrossRef PubMed
  3.Kufe DW (2013) MUC1-C oncoprotein as a target in breast cancer; activation of signaling pathways and therapeutic approaches. Oncogene 32:1073-081. doi:10.-038/?onc.-012.-58 PubMed Central CrossRef PubMed
  4.Horm TM, Schroeder JA (2013) MUC1 and metastatic cancer. Expression, function and therapeutic targeting. Cell Adhes Migr 7:187-98. doi:10.-161/?cam.-3131 CrossRef
  5.Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM (2009) The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15:5323-337. doi:10.-158/-078-0432 CrossRef PubMed
  6.Sinn BV, von Minckwitz G, Denkert C, Eidtmann H, Darb-Esfahani S, Tesch H, Kronenwett R, Hoffmann G, Belau A, Thommsen C, Holzhausen HJ, Grasshoff ST, Baumann K, Mehta K, Dietel M, Loibl S (2013) Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer. Ann Oncol 24:2316-324. doi:10.-093/?annonc/?mdt162 CrossRef PubMed
  7.Siragusa M, Zerili M, Iovino F, Francipane MG, Lombardo Y, Ricci-Vitani L, Di Gesu G, Todero M, De Maria R, Stassi G (2007) MUC1 oncoprotein promotes refractoriness to chemotherapy in thyroid cancer cells. Cancer Res 67:5522-530. doi:10.-158/-008-5472.?CAN-06-4197 CrossRef PubMed
  8.Fessler SP, Wotkowicz MT, Mahanta SK, Bamdad C (2009) MUC1 is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells. Breast Cancer Res Treat 118:113-24. doi:10.-007/?s10549-009-0412-3 CrossRef PubMed
  9.Ren J, Agata N, Chen D, Li Y, Yu WH, Huang L, Raina D, Chen W, Kharbanda S, Kufe D (2004) Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell 5:163-75. doi:10.-007/?s10549-009-0412-3 PubMed Central CrossRef PubMed
  10.Ahmad R, Alam M, Rajabi H, Kufe D (2012) The MUC1-C oncoprotein binds to the BH3 domain of the pro-apoptotic BAX protein and blocks BAX function. J Biol Chem 287:20866-0875. doi:10.-074/?jbc.?M112.-57293 PubMed Central CrossRef PubMed
  11.Agata N, Ahmad R, Kawano T, Raina D, Kharbanda S, Kufe D (2008) MUC1 oncoprotein blocks death receptor-mediated apoptosis by inhibiting recruitment of caspase-8. Cancer Res 68:6136-144. doi:10.-158/-008-5472 PubMed Central CrossRef PubMed
  12.Powró?nik B, Kubowicz P, P?kala E (2012) Monoclonal antibodies in targeted therapy. Postep Hig Med Dosw 66:663-73CrossRef
  13.Campoli M, Ferris R, Ferrone S, Wang X (2010) Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies. Clin Cancer Res 16:11-0. doi:10.-158/-078-0432 PubMed Central CrossRef PubMed
  14.Li GN, Wang SP, Xue X, Qu XJ, Liu HP (2013) Monoclonal antibody-related drugs for cancer therapy. Drug Discov Ther 7:178-84. doi:10.-582/?ddt.-013.?v7.-.-78 PubMed
  15.Pu?kowska A, Bielawski K, Bielawska A, Midura-Nowaczek K (2004) Aromatic analogues of DNA minor groove binders—synthesis and biological evaluation. Eur J Med Chem 39:99-05. doi:10.-016/?j.?ejmech.-003.-1.-05 CrossRef PubMed
  16.Bielawski K, Bielawska A, Sosnowska K, Miltyk W, Winnicka K, Pa?ka J (2006) Novel amidine analogue of melphalan as a specific multifunctional inhibitor of growth and metabolism of human breast cancer cells. Biochem Pharmacol 72:320-31. doi:10.-016/?j.?bcp.-006.-4.-28 CrossRef PubMed
  17.Sienkiewicz P, Bielawski K, Bielawska A, Pa?ka J (2004) Amidine analogue of chlorambucil is a stronger inhibitor of protein and DNA synthesis in breast cancer MCF-7 cells than is the parent drug. Eur J Pharmacol 492:95-01. doi:10.-016/?j.?ejphar.-004.-4.-01 CrossRef PubMed
  18.Bielawska A, Pop?awska B, Sura?yński A, Czarnomysy R, Bielawski K (2010) Cytotoxic efficacy of a novel dinuclear platinum(II) complex in human breast cancer cells. Eur J Pharmacol 643:34-1. doi:10.-016/?j.?ejphar.-010.-6.-22 CrossRef PubMed
  19.Bielawski K, Czarnomysy R, Muszyńska A, Bielawska A, Pop?awska B (2013) Cytotoxicity and induction of apoptosis of human breast cancer cells by novel platinum(II) complexes. Environ Toxicol Pharmacol 35:254-64. doi:10.-016/?j.?etap.-012.-2.-10 CrossRef PubMed
  20.Gornowicz A, Ka?u?a Z, Bielawska A, Gabryel-Porowska H, Czarnomysy R, Bielawski K (2014) Cytotoxic efficacy of a novel dinuclear platinum(II) complex used with anti-MUC1 in human breast cancer cells. Mol Cell Biochem 392:161-74. doi:10.-007/?s11010-014-2018-2 PubMed Central CrossRef Pub
• 作者单位：Agnieszka Gornowicz (1)
  Anna Bielawska (1)
  Robert Czarnomysy (2)
  Halina Gabryel-Porowska (3)
  Anna Muszyńska (2)
  Krzysztof Bielawski (2)
  
  1. Department of Biotechnology, Medical University of Bialystok, Kilinskiego 1, 15-089, Bia?ystok, Poland
  2. Department of Synthesis and Technology of Drugs, Medical University of Bialystok, Kilinskiego 1, 15-089, Bia?ystok, Poland
  3. Deparment of Medical Chemistry, Medical University of Bialystok, Kilinskiego 1, 15-089, Bia?ystok, Poland
  
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Life Sciences
  Biochemistry
  Medical Biochemistry
  Oncology
  Cardiology
  
• 出版者：Springer Netherlands
• ISSN：1573-4919

文摘

New strategy of cancer’s targeting treatment is combining monoclonal antibodies with chemotherapeutic agents. An important goal of targeted therapy appears to be a transmembrane glycoprotein type I—mucin 1 (MUC1), which is overexpressed in tumors of epithelial origin, especially in breast cancer. The goal of the study was to check the effect of monoclonal antibody against MUC1 with novel platinum(II) complex (Pt12) on selected aspects of apoptosis in human MDA-MB-231 breast cancer cells. The number of apoptotic and necrotic cells was measured using annexin V binding assay. The decrease of mitochondrial membrane potential (MMP) and DNA fragmentation was analyzed. Finally, the influence of novel platinum(II) complex (Pt12) used with anti-MUC1 on the concentration of selected markers of apoptosis such as Bax, caspase-8, -9, and caspase-3 was performed using ELISA. The results from combined treatment were compared with those obtained using monotherapy. In our study, we proved that anti-MUC1 used in combination with Pt12 strongly induced apoptosis in MDA-MB-231 breast cancer cell line. The effect was stronger than treatment with Pt12, cisplatin, anti-MUC1, and anti-MUC1 used with cisplatin. We also observed the highest decrease of MMP and the strongest DNA fragmentation after such a combined treatment. The results obtained from ELISA showed increased concentration of Bax, caspases-8, -9, -3 compared to monotherapy. Our study proved that Pt12 together with anti-MUC1 strongly induced apoptosis in estrogen-negative breast cancer cell line (MDA-MB-231). The apoptosis may go through extrinsic pathway associated with caspase-8 as well as intrinsic pathway connected with caspase-9. Keywords Anti-MUC1 Anticancer drugs Platinum complexes Targeted therapy Apoptotic markers